First patients receive experimental cancer drug in groundbreaking trial
NCT ID NCT07182591
Summary
This is the first human trial testing a new cancer drug called DS5361b, both alone and combined with an existing immunotherapy drug (pembrolizumab). The study aims to find the safest dose and see if it helps control advanced solid tumors in people who have run out of standard treatment options. It will enroll 192 adults with specific types of advanced cancer to carefully monitor side effects and early signs of tumor shrinkage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGSarasota, Florida, 34232, United States
-
Research Site
RECRUITINGProvidence, Rhode Island, 02903, United States
-
Research Site
RECRUITINGIrving, Texas, 75039, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
NOT_YET_RECRUITINGFairfax, Virginia, 22031, United States
-
Research Site
RECRUITINGChiba, 277-8577, Japan
-
Research Site
RECRUITINGKōtoku, 135-8550, Japan
Conditions
Explore the condition pages connected to this study.